Annals of the rheumatic diseases
AB1467 EFFECTIVENESS OF TELEMEDICINE IN RHEUMATOLOGY: A MULTI-SITE RANDOMIZED, SINGLE-BLIND, PARALLEL GROUP, NONINFERIORITY TRIAL IN THE UNITED STATES.
POS0391 THE MSQUASH AS MEASUREMENT TOOL FOR DAILY PHYSICAL ACTIVITY: TRANSLATION AND CROSS-CULTURAL ADAPTATION INTO ENGLISH, FIELD-TESTING IN DIFFERENT RHEUMATIC DISEASES AND CLINICAL VALIDATION IN PATIENTS WITH AXIAL SPONDYLOARTHRITIS.
POS0215 LONG-TERM SAFETY AND EFFICACY OF BIMEKIZUMAB IN PATIENTS WITH ACTIVE ANKYLOSING SPONDYLITIS: 5-YEAR RESULTS FROM A PHASE 2B STUDY AND ITS OPEN-LABEL EXTENSION.
AB0913 EFFICACY OF CERTOLIZUMAB PEGOL IN PREVENTING ANTERIOR UVEITIS FLARES COMPARED WITH STANDARD NON-BIOLOGIC TREATMENT: A MATCHED CONTROL STUDY IN HIGH-RISK PATIENTS WITH AXIAL SPONDYLOARTHRITIS.
Goodbye to the term 'ankylosing spondylitis', hello 'axial spondyloarthritis': time to embrace the ASAS-defined nomenclature.
Prevalence of clinically meaningful antiphospholipid antibodies in patients with systemic lupus erythematosus varies by race and ethnicity.
Bimekizumab treatment in patients with active axial spondyloarthritis: 52-week efficacy and safety from the randomised parallel phase 3 BE MOBILE 1 and BE MOBILE 2 studies.
ASAS consensus definition of early axial spondyloarthritis.
POS0657 LONG-TERM SAFETY OF UPADACITINIB IN PSORIATIC ARTHRITIS, ANKYLOSING SPONDYLITIS, AND NON-RADIOGRAPHIC AXIAL SPONDYLOARTHRITIS UP TO 5 YEARS.
OP0243 PROTON PUMP INHIBITOR USE IS ASSOCIATED WITH IMPAIRED BONE MINERAL DENSITY BUT NOT BONE MICROARCHITECTURE IN PATIENTS WITH INFLAMMATORY RHEUMATIC AND MUSCULOSKELETAL DISEASES TAKING GLUCOCORTICOIDS.
